Primary Progressive Multiple Sclerosis

Ocrelizumab Granted Priority Review for Treatment of Multiple Sclerosis

Ocrelizumab Granted Priority Review for Treatment of Multiple Sclerosis

By

If approved, the monoclonal antibody will be the first treatment indicated for both RMS and PPMS.

Ocrelizumab Reduces Disease Activity in Primary Progressive MS

Ocrelizumab Reduces Disease Activity in Primary Progressive MS

By

The new drug shows promise in the treatment of PPMS, for which there are currently no approved treatments.

Mediation of Lipocalin-2 Suggests Therapeutic Target in Progressive MS

Mediation of Lipocalin-2 Suggests Therapeutic Target in Progressive MS

By

Combined results confirmed that intrathecal LCN2 production was increased in MS patients, especially those with SPMS and PPMS.

Tysabri Affects JC Virus Seroconversion in Multiple Sclerosis Patients

Tysabri Affects JC Virus Seroconversion in Multiple Sclerosis Patients

Natalizumab treatment linked to 15.9% increase of value in JC virus.

Targeting Depression May Help Improve Psychosocial Symptoms in MS

Targeting Depression May Help Improve Psychosocial Symptoms in MS

By

The results suggest that addressing depression may help improve other symptoms, like pain and fatigue.

Multiple Sclerosis Clinical Trials More Successful Than Other Diseases

Multiple Sclerosis Clinical Trials More Successful Than Other Diseases

By

MS clinical trials have triple the success rate of those focused on other diseases.

Fingolimod Not Effective in Primary Progressive Multiple Sclerosis

Fingolimod Not Effective in Primary Progressive Multiple Sclerosis

By

There is currently no approved treatments for RMS that have been shown to change the course of the disease.

Sign Up for Free e-newsletters



CME Focus